Ani Pharmaceuticals (ANIP) Non-Current Debt (2012 - 2026)

Ani Pharmaceuticals has disclosed Non-Current Debt across 14 years of filings, most recently posting $280.2 million for Q2 2026.

• In Q2 2026, Non-Current Debt fell 7.07% year-over-year to $280.2 million; the TTM figure through Jun 2026 stood at $280.2 million (down 7.07% YoY), while the FY2025 annual figure was $291.8 million, down 5.59% from the prior year.
• Non-Current Debt came in at $280.2 million for Q2 2026 at Ani Pharmaceuticals, down from $286.0 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $312.9 million in Q3 2024 to a low of $280.2 million in Q2 2026.
• Average Non-Current Debt over 5 years is $291.0 million, with a median of $285.9 million recorded in 2022.
• Year-over-year, Non-Current Debt jumped 69.43% in 2022 and decreased 7.07% in 2026.
• Over 5 years, Non-Current Debt stood at $285.7 million in 2022, then slipped by 0.3% to $284.8 million in 2023, then increased by 8.53% to $309.1 million in 2024, then dropped by 5.59% to $291.8 million in 2025, then retreated by 4.0% to $280.2 million in 2026.
• Per Business Quant data, the three most recent Non-Current Debt figures were $280.2 million in Q2 2026, $286.0 million in Q1 2026, and $291.8 million in Q4 2025.